ESMO 2024: Targeting the Treatment Challenges of Small Cell Lung Cancer - Episode 6
Changing Standard of Care: Potential of Tarlatamab in SCLC Treatment
Panelists discuss how the DeLLphi-301 clinical trial demonstrates an objective response rate of 32% to 40% with tarlatamab, which is clinically meaningful given the rapid onset of responses observed between 5 and 7 weeks, while also considering the implications of a median overall survival of 14 months and the duration of response exceeding 6six months for relapsed or refractory extensive-stage small cell lung cancer.
Video content above is prompted by the following:
3. Dr Leal: Please share your insights on an objective response rate (ORR) range of 32% to 40% among participants in the 10-mg and 100-mg groups of the DeLLPhi-301 clinical trial.
- How clinically meaningful is an objective response observed between 5 and 7 weeks of tarlatamab initiation?
- Please express your views on selecting ORR as the primary end point in this study.
Changing standard of care with tarlatamab
5. Dr Sen: Despite the relatively small numbers of complete response and partial response responders (n=68) in DeLLphi-301, please discuss your opinion on the duration of response (DOR) to tarlatamab at >6 months (59%); at >9 months (29%); and the ongoing response at data cutoff [>50% (n=38)] in the 2 treatment groups?
Related Content:
